Cidara Therapeutics to Participate in September Investor Conferences
Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 4:00 PM ET, and participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 7:00 AM ET. Management will also conduct one-on-one meetings with investors during both events.
Cidara Therapeutics (NASDAQ:CDTX), società biotecnologica specializzata in terapie a base di coniugati farmaco-Fc sviluppate con la piattaforma Cloudbreak®, ha annunciato la sua partecipazione a due conferenze per investitori previste a settembre 2025.
L'azienda terrà una presentazione al H.C. Wainwright 27th Annual Global Investment Conference l'8 settembre alle 16:00 ET e prenderà parte a un fireside chat al Morgan Stanley 23rd Annual Global Healthcare Conference il 9 settembre alle 07:00 ET. Il management inoltre avrà incontri one-to-one con investitori in entrambe le manifestazioni.
Cidara Therapeutics (NASDAQ:CDTX), una empresa biotecnológica especializada en terapias conjugadas fármaco-Fc desarrolladas con su plataforma Cloudbreak®, ha anunciado su participación en dos conferencias para inversores en septiembre de 2025.
La compañía presentará en la H.C. Wainwright 27th Annual Global Investment Conference el 8 de septiembre a las 4:00 PM ET y participará en un fireside chat en la Morgan Stanley 23rd Annual Global Healthcare Conference el 9 de septiembre a las 7:00 AM ET. La dirección también llevará a cabo reuniones individuales con inversores durante ambos eventos.
Cidara Therapeutics (NASDAQ:CDTX)는 Cloudbreak® 플랫폼을 통해 약물-Fc 결합 치료제를 개발하는 바이오테크 회사로, 2025년 9월 개최되는 두 건의 투자자 콘퍼런스에 참가한다고 발표했습니다.
회사는 H.C. Wainwright 27th Annual Global Investment Conference에 9월 8일 동부시간 오후 4시(ET)에 발표를 진행하며, Morgan Stanley 23rd Annual Global Healthcare Conference에서는 9월 9일 동부시간 오전 7시(ET)에 파이어사이드 채팅에 참여합니다. 경영진은 두 행사 모두에서 투자자들과 일대일 미팅도 진행할 예정입니다.
Cidara Therapeutics (NASDAQ:CDTX), une société de biotechnologie spécialisée dans les thérapeutiques conjuguées médicament-Fc via sa plateforme Cloudbreak®, a annoncé sa participation à deux conférences investisseurs en septembre 2025.
La société présentera lors de la H.C. Wainwright 27th Annual Global Investment Conference le 8 septembre à 16h00 ET et prendra part à une table ronde informelle (fireside chat) à la Morgan Stanley 23rd Annual Global Healthcare Conference le 9 septembre à 07h00 ET. La direction tiendra également des rencontres individuelles avec des investisseurs lors des deux événements.
Cidara Therapeutics (NASDAQ:CDTX), ein Biotechnologieunternehmen, das sich auf Wirkstoff–Fc-Konjugat-Therapeutika mittels seiner Cloudbreak®-Plattform spezialisiert hat, hat seine Teilnahme an zwei Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am H.C. Wainwright 27th Annual Global Investment Conference am 8. September um 16:00 Uhr ET präsentieren und an einem Fireside-Chat auf der Morgan Stanley 23rd Annual Global Healthcare Conference am 9. September um 07:00 Uhr ET teilnehmen. Das Management wird zudem während beider Veranstaltungen Einzelgespräche mit Investoren führen.
- None.
- None.
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences.
Details are as follows:
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8, 2025
Time: 4:00 PM ET
Format: Corporate Presentation
Event: Morgan Stanley 23rd Annual Global Healthcare Conference
Date: September 9, 2025
Time: 7:00 AM ET
Format: Fireside Chat
Cidara will also participate in one-on-one investor meetings during the conferences.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025. Additional DFCs have been developed for oncology and in July 2024 Cidara received investigational new drug application clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When is Cidara Therapeutics (CDTX) presenting at the H.C. Wainwright Conference?
What type of presentation will CDTX give at the Morgan Stanley Healthcare Conference?
Will Cidara Therapeutics (CDTX) offer individual investor meetings at these conferences?
What is Cidara Therapeutics' main technology platform?
